EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and validation of a nomogram for posthepatectomy liver failure in hepatocellular carcinoma using ALBI score and muscle-fat composition

Sirui Yang, Huimin Dong, Youwei Wang, Peipei Ye, Shua Cui, Li Guo

Frontiers in Oncology · 20.11.2026 · 16

DOI: 10.3389/fonc.2026.1914426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.11.2026. Verfasst von Sirui Yang und 5 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to develop and internally validate a nomogram integrating the albumin-bilirubin (ALBI) score with muscle-adipose body composition parameters for preoperative prediction of posthepatectomy liver failure (PHLF) in hepatocellular carcinoma (HCC) patients undergoing hepatectomy.

Methods

In this single-center retrospective study, 240 consecutive HCC patients undergoing hepatectomy between June 2022 and September 2025 were enrolled as an available cohort without a priori sample size calculation and randomly allocated to training (n=168) and internal validation (n=72) cohorts at a 7:3 ratio. Body composition was quantified on preoperative CT at the L3 vertebral level, and the visceral-to-skeletal muscle ratio (VSR) was computed as the visceral adipose tissue index divided by the skeletal muscle index. Sixteen candidate preoperative predictors were screened by least absolute shrinkage and selection operator (LASSO) regression and entered into multivariable logistic regression. Model performance was evaluated by the area under the receiver operating characteristic curve (AUC), calibration plots with slope and intercept, the Hosmer-Lemeshow test, a 1, 000-bootstrap optimism-corrected C-index, and decision curve analysis (DCA).

Results

The overall PHLF incidence was 24.6%. LASSO regression identified ALBI score, VSR, and body mass index (BMI) as independent predictors (all P<0.05). The nomogram achieved an AUC of 0.831 (95% CI, 0.762-0.900) in the training cohort and 0.880 (95% CI, 0.794-0.966) in the validation cohort, with an optimism-corrected C-index of 0.821. Calibration was satisfactory, and DCA showed a higher net benefit than the treat-all and treat-none strategies across threshold probabilities of approximately 0.05-0.90. The model outperformed Child-Pugh, MELD, ALBI, PALBI, APRI, and FIB-4 (bootstrap P<0.05 for all pairwise comparisons), retained discrimination for clinically significant grade B/C PHLF (AUC = 0.770, 95% CI: 0.684-0.852), and performed consistently across predefined subgroups of resection extent, liver function, and surgical approach (all interaction P>0.05).

Conclusion

The ALBI-VSR-BMI nomogram showed satisfactory discrimination and calibration for preoperative PHLF prediction in this exploratory single-center cohort with internal split-sample validation. As a readily available preoperative assessment, it may support individualized risk stratification, but its clinical utility remains hypothesis-generating pending temporal and multicenter external validation.

Zitieren

APA

Yang, S., Dong, H., Wang, Y., Ye, P., Cui, S., & Guo, L. (2026). Development and validation of a nomogram for posthepatectomy liver failure in hepatocellular carcinoma using ALBI score and muscle-fat composition. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1914426

Vancouver

Yang S, Dong H, Wang Y, Ye P, Cui S, Guo L. Development and validation of a nomogram for posthepatectomy liver failure in hepatocellular carcinoma using ALBI score and muscle-fat composition. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1914426

BibTeX
@article{Yang2026,
  author = {Yang, Sirui and Dong, Huimin and Wang, Youwei and Ye, Peipei and Cui, Shua and Guo, Li},
  title = {Development and validation of a nomogram for posthepatectomy liver failure in hepatocellular carcinoma using ALBI score and muscle-fat composition},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1914426}
}
Kostenlos starten →